Adherium Highlights Milestones Achieved in Advance of 2018

21 Dec 2017 San Mateo, CA – December 20, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today highlighted milestones achieved in advance of 2018. “As we conclude December and the calendar year, we are accelerating realization of our vision of stronger partnerships between patients and physicians, facilitated […]

AmpliPhi Biosciences Provides Corporate and Strategic Update

 Under single-patient expanded access program, seven patients with serious and life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01 in 2017. Company plans to present topline results in early 2018  Company expects to continue its expanded access clinical strategy in 2018, review data with FDA in mid-2018 and initiate Phase 2 or […]

China Medical System Holdings Limited invests £3.0 million in Destiny Pharma

Posted on 01/12/2017 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]